Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) vector platforms to deliver genetic material intended to address the underlying causes of inherited disorders, with research programs spanning hematology, immunology, metabolic disease and cardiac conditions.

Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone marrow failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune-system disorder; and RP-L301 for pyruvate kinase deficiency, a rare red blood cell disorder. The company has also developed cardiac gene therapy programs, including RP-A501 for Danon disease, a genetic condition that can cause severe cardiomyopathy. Program status and development plans may change as clinical studies and regulatory reviews progress.

Rocket Pharmaceuticals was formerly known as InoMed Pharmaceuticals and adopted its current name in 2015. The company is headquartered in Cranbury, New Jersey, and conducts research, clinical development and regulatory activities in collaboration with medical institutions and partners in the United States and other international markets. Its leadership has included Gaurav Shah, M.D., as chief executive officer.

Key Stats

• Today's Range: $2.58 to $2.75
• 50-Day Range: $2.59 to $3.86
• 52-Week Range: $2.51 to $5.45
• Volume: 2.09 million shs
• Average Volume: 1.77 million shs
• Market Capitalization: $284.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.63
• Consensus Rating: Hold

Rocket Pharmaceuticals Stock Analysis - MarketRank™

Rocket Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 549th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Rocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 3 sell ratings.

Upside Potential

Rocket Pharmaceuticals has a consensus price target of $8.63, representing about 233.0% upside from its current price of $2.59.

Amount of Analyst Coverage

Rocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rocket Pharmaceuticals is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rocket Pharmaceuticals is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rocket Pharmaceuticals has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.19% of the float of Rocket Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently increased by 0.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rocket Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rocket Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.08

News Sentiment

Rocket Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rocket Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $432,273.00 in company stock.

Percentage Held by Insiders

21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/01/2026
• Status update: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RCKT
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: (609) 659-8001
• Fax: 646-224-9585
• Employees: 202
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Rocket Pharmaceuticals: $8.63
• High Price Target: $15.00
• Low Price Target: $3.00
• Potential Upside/Downside: +233.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$223.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.77%
• Return on Assets: -44.92%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 9.24
• Quick Ratio: 9.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.56 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 109,780,000
• Free Float: 86,393,000
• Market Cap: $284.33 million
• Optionable: Optionable
• Beta: 0.50